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Summary
 Background The serum prostate-speciﬁ c antigen (PSA) test is the most commonly used meth-
od for conﬁ rming response of prostate cancer after deﬁ nitive radiation therapy 
(RT). PSA levels are expected to decrease after radiotherapy but usually remain 
detectable. Three consecutive PSA rises above the post-treatment nadir have been 
deﬁ ned as biochemical failure by the ASTRO consensus panel [1]. Rising serum 
PSA concentration after RT does not always indicate treatment failure. Some pa-
tients have a temporary PSA spike, usually within 12–30 months of radiation ther-
apy [2–4]. Most PSA bounces have a magnitude of 1.0ng/mL or less. This obser-
vation was ﬁ rst described by Wallner and colleagues in 1997 [5]. Although this 
phenomenon is a source of anxiety for both the patient and the physician, its rel-
evance to biochemical failure is controversial.
 Aim To determine the clinical and dosimetric factors that predict prostate-speciﬁ c an-
tigen (PSA) bouncing following brachytherapy HDR and three-dimensional con-
formal radiation therapy (3D-CRT) for prostate cancer patients.
 Materials/Methods The evaluated population consisted of 71 hormone-naive patients with a mini-
mum of 2 years of follow-up and at least 6 post-treatment PSA levels. All patients 
were treated using 3D-CRT combined with brachytherapy HDR. A bounce was de-
ﬁ ned as a PSA rise of ≥0.2ng/mL above the nadir followed by a subsequent 120 
decline of ≥0.2ng/mL. Clinical factors evaluated included: patient age, Gleason 
score, maximum initial pretreatment PSA value (iPSAmax), clinical stage, pros-
tate volume, median time to PSA nadir, median PSA nadir value and patient fol-
low-up in months. Dosimetric factors evaluated included the percentage of the 
prostate volume receiving 100% (V100), 150% (V150) and 200% (V200) of the 
prescribed minimal peripheral dose.
 Results Statistically signiﬁ cant predictive factors for PSA bounce were age, V100, V150, 
V200, iPSAmax and median time to PSA nadir. Logistic regression model for mul-
tivariate analysis revealed that only age, iPSAmax and V200 were statistically sig-
niﬁ cant predictors for PSA bounce. There were no statistical differences between 
median nadir among patients who exhibited a PSA bounce and those who did 
not, but non-bouncers reached PSA nadir earlier than bouncers; median time 
was 12.1 vs 17.2 months respectively.
 Conclusion PSA bouncing occurs in approximately one third (1/3) of patients treated with 
3D-CRT and brachytherapy HDR. Bouncing is associated with age, higher pre-
treatment PSA level and increased V200 factor.
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BACKGROUND
The serum prostate-speciﬁ c antigen (PSA) test is 
the most commonly used method for conﬁ rming 
response of prostate cancer after deﬁ nitive radia-
tion therapy (RT). PSA levels are expected to de-
crease after radiotherapy but usually remain de-
tectable. Three consecutive PSA rises above the 
post-treatment nadir have been deﬁ ned as bio-
chemical failure by the ASTRO consensus pan-
el [1]. A rising serum PSA concentration after 
RT does not always indicate treatment failure. 
Some patients have a temporary PSA spike, usu-
ally within 12–30 months of radiation therapy 
[2–4]. Most PSA bounces have a magnitude of 
1.0ng/mL or less. This observation was ﬁ rst de-
scribed by Wallner and colleagues in 1997 [5]. 
Although this phenomenon is a source of anxie-
ty for both the patient and the physician, its rele-
vance to biochemical failure is controversial.
AIM
The purpose of this study was to quantify the 
frequency of bouncing following brachythera-
py HDR and external beam radiation therapy 
and to identify any relationships that may exist 
between bouncing activity and clinical and dosi-
metric factors.
MATERIALS AND METHODS
Patient selection
The records of 189 patients with T1-T2 NxM0 
prostate cancer treated with brachytherapy HDR 
and external beam radiation therapy between 
September 2000 and January 2004 were reviewed. 
This study was limited to the 71 patients with a 
minimum of 2 years of follow-up meeting the fol-
lowing criteria: all had a pretreatment PSA lev-
el, at least 6 post-treatment PSA levels, no neo-
adjuvant or adjuvant hormonal therapy. Patient 
characteristics of the study population are shown 
in Table 1.
Treatment
All patients were treated using three-dimensional 
conformal radiation therapy (3D-CRT) combined 
with brachytherapy HDR (BT-HDR). Patients un-
derwent simulation and were immobilized us-
ing a custom-made immobilization device. This 
 Key words prostate cancer • PSA bounces • brachytherapy
 Full-text PDF: http:/www.rpor.pl/pdf.php?MAN=9699
 Word count: 1792
 Tables: 3
 Figures: —
 References: 25
 Author’s address: Roman Makarewicz, Chair and Clinic of Oncology and Brachytherapy, University of Nicolaus Copernicus 
in Toruń, Collegium Medicum in Bydgoszcz, Romanowskiej 2 Str., 85-796 Bydgoszcz, Poland, 
e-mail: makarewiczr@co.bydgoszcz.pl
Age
 Mean
 Range 
67
47–78
Pretreatment PSA (ng/mL)
 Mean
 Range
 <10
 10–20
 >20
12.1
2.7–38.2
28
21
19
Gleason score
 2–6
 7–10 
43 (60.6%)
28 (39.4%)
T-stage
 T1–T2a
 T2b
50 (70.4%)
21 (29.6%)
Prostate volume [cm3]
 Mean
 Range 
28.7
14.2–60.2 
iPSA [ng/mL]
 Mean
 Median
 Range
14.2
17.4
4.2–60.2 
PSA nadir [ng/mL]
 Mean
 Median
 Range 
0.84
0.47
0.012–2.17 
Table 1. Patients characteristics (N=71).
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was followed by a planning CT scan in the treat-
ment position using 5mm slices. The data were 
transferred to the 3D planning system and the 
prostate, seminal vesicles, bladder and rectum 
were contoured on each image by the physician. 
Dose was reported as the ICRU reference dose. 
Treatment plans were acceptable if the planning 
target volume was encompassed by the 95% isod-
ose surface. Treatment was delivered at 2.0Gy 
daily fractions 5d/week to a total dose of 46 Gy. 
HDR-BT was given in two separate 10Gy fractions 
before and after external beam radiation thera-
py. A dose plan was constructed based on ultra-
sound images. The HDR-BT PTV was equal to 
the CTV and was deﬁ ned as the prostate gland. 
The number of needles and their position were 
deﬁ ned in such a way that CTV was covered by 
the 10Gy isodose line. The BT was performed un-
der spinal anaesthesia. Seven to eighteen needles 
were inserted transperineally guided by transrec-
tal ultrasound. A remote afterloading technique 
was used with an HDR Ir 192 source (Nucletron). 
The total treatment time of ERT and HDR-BT 
was 7–8 weeks.
Follow-up
A bounce was deﬁ ned as a PSA rise of ≥0.2ng/mL 
above the nadir followed by a subsequent decline 
of ≥0.2ng/mL. Bounces were counted if the peak 
occurred in PSA ranges greater than 0.5ng/mL 
and less than 4ng/mL. Patients were followed 
with serum PSA measurement and DRE (digital 
rectal examination) every 3 months after com-
pletion of radiotherapy for the ﬁ rst two years 
and every 6 months thereafter. Serum PSA de-
terminations were by the Abbot assay (normal 0–
4 ng/mL) and all blood was drawn before DRE. 
PSA failure was deﬁ ned according to the ASTRO 
Consensus Panel deﬁ nition [1].
Statistical analysis
Differences in percentages for categorical varia-
bles according to bouncing were evaluated using 
the c2 test. Mann-Whitney U test was used for the 
comparison of differences between the means of 
continuous variables. Logistic regression analysis 
was performed to assess the independent predic-
tive factors for PSA bounce. Statistical signiﬁ cance 
was assigned to p values of 0.05 or less.
RESULTS
The median follow-up time was 32 months (range 
24–60 months). A PSA bounce was detected in 22 
out 71 patients (31%). None of the patients who 
experienced a PSA bounce had a concurrent uri-
nary tract or prostate infection. Patients’ PSA na-
dir before increase ranged from 0.11ng/mL to 
1.55ng/mL (median 0.53ng/mL). There were 
no statistical differences between median nadir 
among patients who exhibited a PSA bounce and 
did not, 0.57ng/mL vs 0.62ng/mL respectively. 
Non-bouncers reached nadir PSA earlier than 
bouncers; median time was 12.1 vs 17.2 months 
respectively. The time from completion of ra-
diation therapy to the start of the spike ranged 
from 7 to 24 months (median 13.5 months). The 
neighed increase of PSA ranged from 0.2ng/mL 
to 0.7ng/mL and was mean 0.28ng/mL.
Relationships between clinical and dosimetric 
data for patients with and without PSA bounces 
are given in Table 2. Statistically signiﬁ cant pre-
dictive factors for PSA bounce were age, V100, 
V150, V200, maximum initial pretreatment PSA 
value (iPSAmax.), median time to nadir PSA. 
These factors were conﬁ rmed in univariate anal-
ysis. Logistic regression for multivariate analysis 
was performed with signiﬁ cant parameters in 
univariate analysis and revealed that only age, 
maximum initial PSA level and V200 were sta-
tistically signiﬁ cant predictors for PSA bounce 
(Table 3).
DISCUSSION
The introduction of serum prostate-speciﬁ c anti-
gen (PSA) determination has changed not only 
the presentation of prostate cancer worldwide but 
also is a useful tool in monitoring prostate can-
cer patients after treatment. PSA level generally 
falls to undetectable levels after surgery, but for 
patients treated with radiation therapy PSA level 
often decreases slowly and steadily [6]. Some of 
them can experience a temporary elevation in se-
rum PSA without biochemical or clinical failure. 
This phenomenon, called a PSA bounce or PSA 
spike, occurs in up to 35% of patients undergo-
ing brachytherapy [2,4,6–8] and 12% to 54% of 
men undergoing external beam radiation thera-
py [9–16]. In most papers the frequency of PSA 
bounce seems to be higher after brachytherapy 
than after EBRT. Insertions of needles or seeds 
might cause an inﬂ ammatory reaction leading 
to prostatitis and elevated PSA concentration. 
The aetiology for PSA bounce remains unclear, 
although bacterial and radiation proctitis have 
been postulated as possible mechanisms [4,7] A 
PSA bounce can be difﬁ cult to distinguish from 
biochemical failure, leading to signiﬁ cant patient 
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and clinician anxiety with possible unnecessary 
therapeutic intervention. No universally accept-
ed deﬁ nitions exist for PSA bounce. PSA increase 
in the range of 0.1ng/mL [7], 0.2ng/mL [4,17], 
0.4ng/mL and ≥15% of the preceding value [18] 
have been described as a PSA bounce by differ-
ent authors. Knowledge of the aetiology and pre-
dictors of PSA bounces will help to understand 
and predict this phenomenon and to alleviate 
patient and clinician anxiety.
Bounce frequencies using different deﬁ nitions 
are reported to be in the range of 12–54% 
[4,8–10,13,14,18,19]. The bounce rate observed 
in our study was 31%. 19 patients experienced a 
single bounce and 3 patients 2 bounces. The rel-
Factor No spike (N=49) Mean ±SD Spike (N=22) Mean ±SD P
Age [years]  68.5±12.1  62±10.2 0.001
Gleason score
Prostate volume
 5.2±1.2
 27.7±11.3
 5.9±1.3
 28.4±12.1
0.842
0.741
iPSA max*  14.7±12.1  16.7±10.2 0.045
 V100
 V150
 V200
 29.4±11.2
 11.4±4.2
 6.2±2.1
 34±12.2
 12.4±3.9
 8.1±2.3
0.041
0.049
0.021
Follow-up [months]  32.5±7.2  33.1±6.1 0.062
Median nadir PSA [ng/mL] 0.57 0.62 0.072
Nadir PSA [ng/mL]
 ≤0.5
 >0.5
23 (58.3%)
26 (41.7%)
10 (45.5%)
12 (54.5%)
0.094
Tstage
 T1–2a
 T2b
35 (71.4%)
14 (28.6%)
14 (63.6%)
8 (36.4%)
0.08
Median time to nadir PSA 12.1 17.2 0.002
Table 2. Clinical and dosimetric data for patients with and without PSA bounces.
* iPSA max – initial maximal PSA.
Factor
Univariate analysis Multivariate analysis
p-value Relative risk 95% CI p-value
Age (≤65 vs >65) 0.004 1.82 1.52–4.28 0.003
Gleason score (≤6 vs ≥7) 0.092 – – –
Tstage (T1–2a vs T2b) 0.421 – – –
iPSA max* 0.019 1.21 0.86–1.42 0.002
D90 0.771 – – –
D100 0.770 – – –
V100 0.022 – – –
V150 0.042 – – –
V200 0.002 1.22 0.89–1.32 0.002
Median time to nadir (<15 mo vs ≥15mo) 0.039 – – –
Table 3. Analysis of factors predicting PSA bounce.
* iPSA max – initial maximal PSA.
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atively high bounce rate in our study may be re-
lated to the deﬁ nition of bounce that we used. As 
already mentioned, the deﬁ nition of PSA bounce 
varies widely in published reports and every choice 
of deﬁ nition may be problematic. Hanlon et al. 
used a deﬁ nition of at least a 0.4ng/mL increase 
with any decline below that level and found an 
association between PSA bounce and biochem-
ical failure [9,10]. According to Patel et al. this 
value is too high and may reﬂ ect a meandering 
PSA after treatment that may really be an errat-
ic pathway toward PSA failure [20]. Critz et al. 
used a deﬁ nition of at least a 0.1ng/mL rise with 
a decline to or below that level, but it seems that 
ﬂ uctuations of 0.1ng/mL were too low because 
this was within the error of the assay [7,8,19]. In 
such circumstances we chose a deﬁ nition of rise 
of 0.2ng/mL followed by decline as the most rea-
sonable deﬁ nition. We detected a higher bounce 
frequency in younger patients. Perhaps younger 
patients have more androgen production which 
affects the bounce phenomenon. None of the pa-
tients who experienced a PSA increase developed 
biochemical failure. This association has been 
conﬁ rmed by different authors [2,3,21,22]. On 
the other hand, Rosser et al. did not ﬁ nd that age 
has a signiﬁ cant impact on the development, du-
ration or magnitude of PSA bounce [13]. There 
are also other hypotheses regarding greater sex-
ual activity [17,19] or delayed apoptotic event 
[20]. The median time to bounce occurred at 
15 months after completion of radiation therapy. 
Our observed median time to bounce is consistent 
with the range of values reported in studies of pa-
tients treated with EBRT alone and brachytherapy 
ranged from 1.5 to 2.6 years [9,10,13,16,18,21]. 
In our study 9% of bounces occurred in the ﬁ rst 
year after RT, 82% in the second year and 9% in 
the third year or longer time of follow-up. The 
peak of appearance of bouncing PSA in second 
year of follow-up may be due to a different rea-
son. According to Merrick benign prostatic ele-
ments such as BPH (benign prostate hyperplasia) 
could respond to radiation with PSA kinetics dif-
ferent to those of malignant cells [22]. It is highly 
probable that areas of necrosis identiﬁ ed in BPH 
nodules could have resulted in PSA bounces with 
the suggestion that radiation-induced cell death 
in BPH elements may occur at a later time inter-
val than malignant cells.
None of our patients who experienced a PSA 
bounce had biochemical or clinical failure. The 
present study was limited by the short median time 
of follow-up. With longer follow-up, more patients 
may develop biochemical or clinical failure, per-
haps including some of the patients now thought 
to have had a PSA bounce. The relationship of 
bouncing to bNED (biochemical no evidence of 
disease) control was investigated by Hanlon et al. 
[9,10]. According to them bNED rates were for 
bouncers and non-bouncers 52% and 69% re-
spectively. This observation was not conﬁ rmed by 
other authors [3,4,8,15,18]. Even when the pres-
ence of rising PSA is combined with a histological-
ly positive biopsy in the ﬁ rst year after brachyther-
apy, it may not mean persistence of viable cancer 
cells [23,24]. In the other studies bNED control 
was even better in bouncers [14,25].
In our study we demonstrated the volume of the 
prostate gland receiving 200% of the prescription 
dose (V200) predicted for PSA bounce. Merrick 
et al. found that V150 was a signiﬁ cant predictor 
of PSA spike [2]. These observations suggest that 
PSA bounces may be associated with intraprostatic 
postimplant healthy tissue necrosis or transition 
from sublethal to lethal cancer cellular damage, 
in which case patients with PSA bounce should 
have better prognosis. Such clinical observation 
was made by Rosser but further pathological stud-
ies are needed to prove this hypothesis [14].
CONCLUSION
Nearly one third of patients after brachythera-
py HDR combined with conformal external ra-
diation therapy experienced the PSA bounce 
effect. As a result, PSA failure could potentially 
have been overestimated in this group. To mini-
mize this problem clinicians should be aware of 
this phenomenon. When a prostate cancer pa-
tient treated with radiation therapy presents an 
elevation in PSA, the detailed history should be 
known to rule out different reasons connected 
with elevated PSA level.
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